Updated: Novartis rejigs late-stage plans for Cosentyx, next-gen CAR-T, TIGIT antibody and more
Novartis has cleaned up its Phase III slate, shelving late-stage plans for programs across inflammatory diseases and cancer, the Swiss pharma giant
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
